레보도파 시장 : 형태별, 투여 경로별, 유통 채널별 - 세계 기회 분석과 산업 예측(2023-2032년)

The global levodopa market is anticipated to reach $2,934.6 million by 2032, growing from $1,655.4 million in 2022 at a CAGR of 6.1% from 2023 to 2032.

Levodopa, commonly called L-Dopa, is a chemical building block converted into dopamine in the body. Dopamine is a chemical messenger secreted in the brain. It facilitates pleasure, brain function, and memory processes. Almost all patients get levodopa, a dopamine precursor that effectively controls Parkinson's disease (PD) symptoms in its early stages. Carbidopa is frequently used in combination with levodopa-containing medications to increase their efficacy by decreasing dopamine metabolism.

The levodopa market has been witnessing significant growth, owing to rise in investments in healthcare infrastructure, increase in disposable income, and surge in healthcare access in emerging markets. Moreover, as emerging economies bolster their healthcare systems, increase in availability and affordability of medications such as levodopa for Parkinson's disease management. Improved access to healthcare services translates into greater diagnosis rates and treatment initiation, consequently driving the demand for levodopa. Furthermore, increase in disposable income empowers individuals to afford essential medications, driving the market growth. In addition, the combination of these factors not only expands the patient pool but also creates new growth opportunities for pharmaceutical companies operating in the levodopa market, particularly in regions with evolving healthcare infrastructures. However, high cost associated with levodopa is one of the key factors restraining the growth of the levodopa market. Moreover, affordability issues limit patient access to this crucial medication for Parkinson's disease management, particularly in regions with limited healthcare resources and low-income populations. Furthermore, the financial problem of levodopa prevents patients from seeking consistent treatment or adhering to prescribed regimens, leading to suboptimal disease management outcomes. In addition, the high cost may strain healthcare budgets and limit reimbursement options, restraining market growth. Moreover, addressing the affordability barrier is imperative to ensure equitable access to levodopa and mitigate its impact on market growth and patient care.

On the contrary, increase in technological advancements in drug delivery systems promise to enhance levodopa's efficacy and patient adherence through innovative formulations and alternative administration routes are expected to drive the market growth. Furthermore, rise in healthcare expenditure, especially in developing regions, facilitates greater accessibility to levodopa, driving the market growth. In addition, emerging markets, coupled with increase in geriatric population, offer untapped potential for market penetration. Moreover, ongoing research initiatives and channel developments exploring novel formulations and combination therapies bolster levodopa's market prospects. Furthermore, supportive healthcare policies and reimbursement frameworks ensure widespread accessibility, while increase in disease awareness and diagnosis rates contribute to the market growth.

The key players operating in the levodopa market include Novartis AG, Merck & Co. Inc., Eli Lilly & Company, Bristol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., Impax Laboratories Inc., Pfizer Inc., UCB SA, Sun Pharmaceutical Industries Ltd., and Mylan NV. In addition, the market players are increasingly focusing on adopting strategies such as collaborations and acquisitions to gain a competitive edge in the market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the levodopa market analysis from 2022 to 2032 to identify the prevailing levodopa market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the levodopa market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global levodopa market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Analysis of raw material in a product (by %)
• Investment Opportunities
• Technology Trend Analysis
• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• List of customers/consumers/raw material suppliers- value chain analysis
• Market share analysis of players at global/region/country level

Key Market Segments

By Form

• Tablets
• Capsules
• Powder
• Liquid

By Route of Administration

• Oral
• Parenteral

By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Novartis AG
• Merck and Co. Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Co.
• Teva Pharmaceutical Industries Ltd.
• Impax Laboratories Inc.
• Pfizer Inc.
• UCB SA
• Sun Pharmaceutical Industries Ltd.
• Mylan Nv

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities
• 3.5. Average Selling Price
• 3.6. Market Share Analysis
• 3.7. Brand Share Analysis
• 3.8. Trade Data Analysis
• 3.9. Product Consumption
• 3.10. Value Chain Analysis
• 3.11. Regulatory Guidelines
• 3.12. Key Regulation Analysis
• 3.13. Reimbursement Scenario
• 3.14. Patent Landscape

CHAPTER 4: LEVODOPA MARKET, BY FORM

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Tablets
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Capsules
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Powder
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Liquid
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Oral
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Parenteral
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: LEVODOPA MARKET, BY DISTRIBUTION CHANNELS

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Pharmacies
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Other
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: LEVODOPA MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Form
  • 7.2.3. Market size and forecast, by Route of Administration
  • 7.2.4. Market size and forecast, by Distribution Channels
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Form
    • 7.2.5.1.2. Market size and forecast, by Route of Administration
    • 7.2.5.1.3. Market size and forecast, by Distribution Channels
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Form
    • 7.2.5.2.2. Market size and forecast, by Route of Administration
    • 7.2.5.2.3. Market size and forecast, by Distribution Channels
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Form
    • 7.2.5.3.2. Market size and forecast, by Route of Administration
    • 7.2.5.3.3. Market size and forecast, by Distribution Channels
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Form
  • 7.3.3. Market size and forecast, by Route of Administration
  • 7.3.4. Market size and forecast, by Distribution Channels
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Form
    • 7.3.5.1.2. Market size and forecast, by Route of Administration
    • 7.3.5.1.3. Market size and forecast, by Distribution Channels
    • 7.3.5.2. UK
    • 7.3.5.2.1. Market size and forecast, by Form
    • 7.3.5.2.2. Market size and forecast, by Route of Administration
    • 7.3.5.2.3. Market size and forecast, by Distribution Channels
    • 7.3.5.3. France
    • 7.3.5.3.1. Market size and forecast, by Form
    • 7.3.5.3.2. Market size and forecast, by Route of Administration
    • 7.3.5.3.3. Market size and forecast, by Distribution Channels
    • 7.3.5.4. Spain
    • 7.3.5.4.1. Market size and forecast, by Form
    • 7.3.5.4.2. Market size and forecast, by Route of Administration
    • 7.3.5.4.3. Market size and forecast, by Distribution Channels
    • 7.3.5.5. Italy
    • 7.3.5.5.1. Market size and forecast, by Form
    • 7.3.5.5.2. Market size and forecast, by Route of Administration
    • 7.3.5.5.3. Market size and forecast, by Distribution Channels
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Form
    • 7.3.5.6.2. Market size and forecast, by Route of Administration
    • 7.3.5.6.3. Market size and forecast, by Distribution Channels
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Form
  • 7.4.3. Market size and forecast, by Route of Administration
  • 7.4.4. Market size and forecast, by Distribution Channels
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. China
    • 7.4.5.1.1. Market size and forecast, by Form
    • 7.4.5.1.2. Market size and forecast, by Route of Administration
    • 7.4.5.1.3. Market size and forecast, by Distribution Channels
    • 7.4.5.2. Japan
    • 7.4.5.2.1. Market size and forecast, by Form
    • 7.4.5.2.2. Market size and forecast, by Route of Administration
    • 7.4.5.2.3. Market size and forecast, by Distribution Channels
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Form
    • 7.4.5.3.2. Market size and forecast, by Route of Administration
    • 7.4.5.3.3. Market size and forecast, by Distribution Channels
    • 7.4.5.4. South Korea
    • 7.4.5.4.1. Market size and forecast, by Form
    • 7.4.5.4.2. Market size and forecast, by Route of Administration
    • 7.4.5.4.3. Market size and forecast, by Distribution Channels
    • 7.4.5.5. Australia
    • 7.4.5.5.1. Market size and forecast, by Form
    • 7.4.5.5.2. Market size and forecast, by Route of Administration
    • 7.4.5.5.3. Market size and forecast, by Distribution Channels
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Form
    • 7.4.5.6.2. Market size and forecast, by Route of Administration
    • 7.4.5.6.3. Market size and forecast, by Distribution Channels
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Form
  • 7.5.3. Market size and forecast, by Route of Administration
  • 7.5.4. Market size and forecast, by Distribution Channels
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Form
    • 7.5.5.1.2. Market size and forecast, by Route of Administration
    • 7.5.5.1.3. Market size and forecast, by Distribution Channels
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Form
    • 7.5.5.2.2. Market size and forecast, by Route of Administration
    • 7.5.5.2.3. Market size and forecast, by Distribution Channels
    • 7.5.5.3. United Arab Emirates
    • 7.5.5.3.1. Market size and forecast, by Form
    • 7.5.5.3.2. Market size and forecast, by Route of Administration
    • 7.5.5.3.3. Market size and forecast, by Distribution Channels
    • 7.5.5.4. South Africa
    • 7.5.5.4.1. Market size and forecast, by Form
    • 7.5.5.4.2. Market size and forecast, by Route of Administration
    • 7.5.5.4.3. Market size and forecast, by Distribution Channels
    • 7.5.5.5. Rest of LAMEA
    • 7.5.5.5.1. Market size and forecast, by Form
    • 7.5.5.5.2. Market size and forecast, by Route of Administration
    • 7.5.5.5.3. Market size and forecast, by Distribution Channels

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Novartis AG
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
• 9.2. Merck and Co. Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
• 9.3. Eli Lilly and Company
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
• 9.4. Bristol-Myers Squibb Co.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
• 9.5. Teva Pharmaceutical Industries Ltd.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
• 9.6. Impax Laboratories Inc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
• 9.7. Pfizer Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
• 9.8. UCB SA
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
• 9.9. Sun Pharmaceutical Industries Ltd.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
• 9.10. Mylan Nv
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot